Evidence of FOXA1 involvement in tumor progression on the (epi)genetic, transcriptomic, and proteomic levels warrants further investigation of FOXA1 as clinical biomarker and its clinical utility for DCIS risk stratification. This evidence concerns the gene FOXA1 and ductal breast carcinoma in situ.